Results 161 to 170 of about 147,258 (248)

Irgm1 Improves Postinfarction Cardiac Repair by Promoting Neutrophil Clearance and Efferocytosis

open access: yesAdvanced Science, EarlyView.
The Irgm1‐PDIA3 axis enhances post‐infarction cardiac repair by accelerating neutrophil clearance and facilitating efferocytosis. Irgm1 holds potential as a prognostic biomarker in MI, and LOC14 may represent a therapeutic option to improve cardiac repair, especially in cases of Irgm1 deficiency.
Zeng Wang   +14 more
wiley   +1 more source

Endogenous “Time Bomb” – Mislocalized Phospholipase A2 as a Critical Mediator of Ultra‐Rapid Mortality in Sepsis and Acute Lung Injury

open access: yesAdvanced Science, EarlyView.
Phospholipase A2 (PLA2), a dormant enzyme, becomes lethal when activated—collapsing lungs in minutes. Our dual therapy (DOPS + varespladib) boosts survival from 0% to >90% in sepsis/ALI. A breakthrough for acute lung injury treatment. ABSTRACT This study reveals that phospholipase A2 (PLA2), normally stable and nontoxic, can be activated specifically ...
Jianyu Wang   +7 more
wiley   +1 more source

Editorial: Interferon-λs: New Regulators of Inflammatory Processes

open access: yesFrontiers in Immunology, 2019
Ivan Zanoni, Charlotte Odendall
doaj   +1 more source

Liposomal Nanoconfinement Enables Type I Photodynamic Conversion for Synergistic Cancer Photothermal‐Immunotherapy

open access: yesAdvanced Science, EarlyView.
Liposomal nanoconfinement converts the hemicyanine photosensitizer RhM from Type‐II to Type‐I photodynamic therapy (PDT) while enhancing photothermal therapy (PTT). The RhM‐R837@Lip nanoassembly efficiently generates superoxide (O2•−) and hydroxyl radicals (•OH) to kill tumor cells and achieve tumor ablation.
Minglu Zhang   +14 more
wiley   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

open access: yesAdvanced Science, EarlyView.
This study introduces Cadict, an EGFR‐targeted nanodrug that co‐delivers cuproptosis and disulfidptosis inducers to overcome immune resistance. Cadict synergistically enhances tumor cytotoxicity and sensitizes cancers to ICIs by upregulating PD‐L1 via an Eif5b‐dependent translation mechanism, fostering a potent antitumor immune response and ...
Shaoqing Huang   +12 more
wiley   +1 more source

SINE RNA of the imprinted miRNA clusters mediates constitutive type III interferon expression and antiviral protection in hemochorial placentas. [PDF]

open access: yesCell Host Microbe
Wickramage I   +15 more
europepmc   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

open access: yesAdvanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong   +5 more
wiley   +1 more source

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

open access: yesAdvanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

OTUD6A in Airway Epithelial Cells Exacerbates Allergic Asthma by Promoting Airway Inflammation and Airway Remodeling Through Deubiquitination of hResistin/mRELMα

open access: yesAdvanced Science, EarlyView.
This study elucidates a novel mechanistic role of the deubiquitinase OTUD6A in asthma pathogenesis, uncovering its regulatory function in airway inflammation and airway remodeling through the stabilization of hResistin/mRELMα. This study offers a novel regulatory axis (OTUD6A‐hResistin/mRELMα) in asthma pathogenesis and OTUD6A inhibition as a potential
Weiting Pan   +10 more
wiley   +1 more source

Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses. [PDF]

open access: yesJ Immunother Cancer
Wang B   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy